CD30 Antibody (6A23): sc-70628

CD30 Antibody (6A23) is a mouse monoclonal IgG1 antibody that detects CD30 in human samples through immunofluorescence (IF) and flow cytometry (FCM) applications. CD30 is a member of the tumor necrosis factor receptor family and is primarily expressed on activated T and B lymphocytes, as well as in neoplastic cells associated with Hodgkin′s lymphoma and other hematologic malignancies. The presence of CD30 on these cells is crucial as CD30 serves as a marker for diagnosis and prognosis in various lymphoproliferative disorders. Upon binding with CD30L, CD30 initiates signaling pathways that can lead to cell proliferation, survival, and differentiation, highlighting CD30′s role in immune regulation and potential therapeutic targeting. The interaction between CD30 and CD30L is particularly significant in the context of Hodgkin′s lymphoma, where CD30 expression is associated with tumor growth and progression. Anti-CD30 antibody (6A23) is therefore an essential tool for researchers studying the mechanisms of immune response and the pathology of related malignancies, providing insights into the therapeutic potential of targeting CD30 in cancer treatment.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD30 Antibody (6A23) References:

1. CD30 as a therapeutic target for lymphoma.  |  Schirrmann, T., et al. 2014. BioDrugs. 28: 181-209. PMID: 24043362
2. Cutaneous CD30-Positive Lymphoproliferative Disorders.  |  Kempf, W. 2014. Surg Pathol Clin. 7: 203-28. PMID: 26837199
3. CD30-Positive Lymphoproliferative Disorders.  |  Nikolaenko, L., et al. 2019. Cancer Treat Res. 176: 249-268. PMID: 30596222
4. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.  |  Kerbauy, LN., et al. 2021. Clin Cancer Res. 27: 3744-3756. PMID: 33986022
5. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies.  |  Schwarting, R., et al. 2022. Arch Pathol Lab Med. 146: 415-432. PMID: 35299246
6. CD30 expression in cutaneous B-cell lymphomas.  |  Afolayan-Oloye, O., et al. 2023. J Cutan Pathol. 50: 819-827. PMID: 37290910
7. The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment.  |  Dumitru, AV., et al. 2023. Cells. 12: PMID: 37443818
8. CD30 in Cutaneous Pathology.  |  Fernandez-Flores, A. and Cassarino, D. 2023. Am J Dermatopathol. 45: 593-607. PMID: 37625801
9. Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.  |  Montes-Moreno, S. 2023. Pathologie (Heidelb). 44: 136-139. PMID: 38010388
10. Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas.  |  Li, Z., et al. 2023. Front Oncol. 13: 1301437. PMID: 38188299

The preferred CD30 antibody is CD30 Antibody (Ber-H2): sc-19658.